Table 1: Demographic and baseline clinical characteristics of participants.
| Characters | Frequency | Percent | 95% CI |
| Sex | |||
| Male | 69 | 47.9 | 36.9,56.3 |
| Female | 75 | 52.1 | 43.8,60.8 |
| Baseline Functional status | |||
| Working | 69 | 47.9 | 40.3,56.3 |
| Ambulatory | 58 | 40.3 | 31.9,47.9 |
| Bedridden | 17 | 11.8 | 6.9,17.4 |
| WHO clinical stage | |||
| Stage I | 31 | 21.5 | 14.6,27.8 |
| Stage II | 36 | 25 | 18.1,31.9 |
| Stage III | 58 | 40.3 | 32.6,48.6 |
| Stage IV | 19 | 13.2 | 7.6,19.4 |
| TB-co infection | |||
| Yes | 55 | 38.2 | 30.6,45.8 |
| No | 89 | 61.8 | 54.2,69.4 |
| Illegible for ART | |||
| Clinical | 68 | 47.2 | 38.9,54.9 |
| CD4 count† | 70 | 48.6 | 41.0,56.9 |
| TLC* | 5 | 3.5 | 0.7,6.9 |
| Transfer in | 1 | 0.7 | 0.0,2.1 |
| Total | 144 | 100 | 100.0,100.0 |
†Cluster Differentiation cells; *Total Lymphocyte count.